

AIM HIGHer

<u>INVESTIGATORS</u>	<ul style="list-style-type: none"> • Dinesh Sharma, MD- Principal Investigator • Viviana Navas, MD- Sub Investigator • Samantha Sublette, MD- Sub Investigator • Luis Rechani, MD- Sub Investigator
<u>Trial Objective</u>	<p>Evaluate the efficacy and safety of Cardiac Contractility Modulation (CCM) therapy in patients with symptomatic HF40-60 (HF with LVEF 40-60%).</p>
<u>Randomization</u>	<ul style="list-style-type: none"> • 2:1 Randomization ratio
<u>Key Inclusion</u>	<ul style="list-style-type: none"> • Diagnosed with symptomatic heart failure; • LVEF\geq and\leq 60% (as assessed by echo core lab) • A .Heart Failure Hospitalization within 12 months prior to study OR Urgent heart Failure visit requiring IV therapy within 6 months prior to study consent, an elevated BMI-adjusted natriuretic peptide values OR • B. If there is no heart failure hospitalization within 12 months, an elevated BMI-adjusted natriuretic peptide value must be achieved
<u>Key Exclusion</u>	<ul style="list-style-type: none"> • Resting ventricular rate <50 or >110bpm • Resting systolic blood pressure <100 or>160 mmHG • BMI greater than 46 • Any Severe valvular stenotic disease or any severe valvular regurgitation • Mechanical tricuspid valve • Unable to walk at least 100 meters or walk more than 450 meters during a 6MWT • Hypertrophic infiltrative/restrictive • Receiving CRT • Dialysis(permanent) or GFR <20 ML/min 1.73m²